OpenArc Corporate Advisory’s Astria Therapeutics ATXS Stock Holding History

OpenArc Corporate Advisory’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,689	Closed	-$166K	–	719
2025 Q4	$166K	Buy	+12,689	New	+$152K	﹤0.01%	629

OpenArc Corporate Advisory's ATXS Position: Q1 2026 in Review

OpenArc Corporate Advisory sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 12,689 shares — an estimated $166K sold.

OpenArc Corporate Advisory first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $166K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

OpenArc Corporate Advisory reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
OpenArc Corporate Advisory sold 12,689 Astria Therapeutics shares in Q1 2026, an estimated $166K.
OpenArc Corporate Advisory first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
OpenArc Corporate Advisory's Astria Therapeutics position peaked at $166K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q1 2026, filed 11 May 2026.